An estimated 580,000 people fell ill with multidrug-resistant (MDR) forms of tuberculosis (TB) in 2015, including 100,000 with rifampicin-resistant TB (RR-TB). Only 132,000 cases of MDR-TB were diagnosed, and only 125,000 people began MDR-TB treatment. An estimated 250,000 people died from MDR/RR-TB in 2015.
Conventional MDR-TB treatments last almost 24 months and are associated with severe side effects and poor outcomes. Two newer drugs – bedaquiline and delamanid – can help increase cure rates and reduce mortality, but scale-up is lagging for several reasons. Médecins Sans Frontières (MSF) estimates that less than 5% of people with MDR-TB who could have benefitted from these lifesaving newer medicines were treated with them in 2016.
This issue brief examines current opportunities to optimise MDR-TB treatment and to address the persistent access challenges that put treatment out of reach for people struggling to survive this deadly disease.
“The power of data to fight tobacco”
Interested in a specific country or countries? Find out which tobacco control measures match the country you are looking for.
Interested in specific tobacco control measures? Find out which countries match what you are looking for.
WHO has developed a new health kit to support treatment for chronic disease patients in emergency settings. The prevalence of NCDs is increasing worldwide, including in emergency/crisis-prone areas. Yet current humanitarian response has not accounted for this emerging burden. Current emergency health kits, including the Interagency emergency health kit (IEHK) 2015 do not contain enough and adequate medicines to manage the most commonly encountered NCDs in primary health care. Consequently, the NCD kit attends to cover this gap by providing essential medicines and medical devices for the management of hypertension and cardiac conditions, diabetes and endocrine conditions, chronic respiratory diseases, and mental health and neurological conditions.
The NCD Kit content list can be downloaded under: http://www.who.int/entity/emergencies/kits/ncd-2016-content-list.pdf?ua=1
The basic NCD kit is intended for outpatient care in a variety of primary health care settings, such as mobile clinics and primary health care units, particularly to refill ongoing treatment regimens. It contains oral medicines, basic diagnostic equipment, renewables and additional products needing cold chain, such as insulin, accompanied with treatment guidelines. Only medicines included in the WHO Model list of essential medicines 2015 are available in the kit. The selection of medicines has been aligned with the WHO Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low-resource settings and the WHO mhGAP humanitarian intervention guide for mental health management, including treatment of psychosis, depression and epilepsy. This allows a standardized evidence-based kit.
This concept note describes the methods used to assess the prevalence of any HIVDR and HIVDR by PMTCT exposure among children less than 18 months of age using remnant dried blood spot specimens from early infant diagnosis over a 12-month period
WHO’s mhGAP Intervention Guide 2.0 app, launched in October, is now available in both iOS and Android. The app provides non-specialized health-care providers with access to comprehensive information to help them diagnose and treat a range of mental, neurological and substance use (MNS) disorders including depression, epilepsy and dementia from their tablets or mobile phones. Each module includes a description and guidance on assessment and management of priority MNS conditions. The tool can be downloaded free of charge. It is currently available in English. Other languages are expected to be available soon
Download the iOS Version under: https://itunes.apple.com/gb/app/mhgap-ig-2-0-app-e-mhgap/id1291414206?mt=8
The Android Version under: https://play.google.com/store/apps/details?id=com.universaltools.mhgap
Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436
This third edition of the Unitaid/WHO market and technology landscape: HIV rapid diagnostic tests for self-testing report summarizes the current HIV testing gap; the challenges facing efforts to scale up; and the potential role HIV self-testing (HIVST) could play to achieve the United Nation’s 90-90-90 targets. In particular, the report synthesises the existing and emerging market demand and supply of kits.
The information in this report is intended for manufacturers, donors, national programmes, researchers and other global health stakeholders who are exploring the potential role of HIVST.
2nd edition. These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care